Abstract:The purpose of this study is to investigate whether the radiomics approach could predict brain metastases (BM) for Stage III/IV non-small cell lung cancer (NSCLC) patients with ALK mutation. Patients in stage III/IV NSCLC with ALK mutation confirmed by pathology from 2012 to 2017 were enrolled retrospectively. All patients’ CT before treatment were collected and the gross tumor volume (GTV) was defined by two experienced radiologists. Patients were divided into two datasets, one for model training and another for model test. A test-retest in RIDER NSCLC dataset was performed to find 132 stable radiomics features whose ICC value was more than 0.9. Then the LASSO Cox regression and a leave-one-out cross-validation were conducted to find optimal features for logistic regression model，which was then conducted to evaluate the predictive value of radiomics feature(s) for BM. AUC was calculated to evaluate model performance. Cox regression model was used to describe correlations between feature(s) with freedom from brain metastases (FFBM), and log-rank test was implemented for stratified analysis. A total of 132 patients were included in this study, among which 27 patients had BM at baseline examination. The median follow-up time was 12.7 (IQR 4.5-26.6) months. In the train set we found one radiomics feature (W_GLCM_LH_Correlation) significantly correlated with BM (P=0.014, AUC=0.6736) and it also had favorable performance in the test set (AUC=0.6417). The predictive value of radiomics feature could be further improved when combined with T stage and N stage (train set: AUC=0.73, test set: AUC=0.70). Those 105 patients without brain metastases before treatment were divided by their overall stage into stage III (57) and stage IV (48) groups. The radiomics feature had moderate performance to predict brain metastases during or after treatment in two groups (Stage III: AUC=0.6799; Stage IV: AUC=0.6556)，implying that the feature correlated with pretreatment BM also had stable predictive power in the follow-up observation. What’s more, all stage III patients could be developed into low risk or high risk according to cox regression model developed by combing radiomics feature and treatment characteristics (chemotherapy and radiotherapy). Log-rank p-value was 0.021. We find one radiomics feature derived from pretreatment chest CT to be predictable for brain metastases in stage III/IV NSCLC patients with ALK mutation, which could be beneficial to risk stratification for such patients. Further investigation is needed.

A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma

Prognosis of lung cancer with simple brain metastasis patients and establishment of survival prediction models: a study based on real events

Prediction of brain metastasis development with DNA methylation signatures

Characterization of Evolution Trajectory and Immune Profiling of Brain Metastasis in Lung Adenocarcinoma

Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients

Multi-omics with Dynamic Network Biomarker Algorithm Prefigures Organ-Specific Metastasis of Lung Adenocarcinoma

P1.11-03 Proteomics-based Predictive Model for the Increased Brain Metastasis Risk in Resected Lung Adenocarcinoma with EGFR Mutaion

A novel basement membrane-related gene signature for prognosis of lung adenocarcinomas

Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma

Screening and identifying a novel M-MDSCs-related gene signature for predicting prognostic risk and immunotherapeutic responses in patients with lung adenocarcinoma

Molecular Predictors of Brain Metastasis-Related Micrornas in Lung Adenocarcinoma.

A Nomogram Model for Diagnosing Bone Metastasis in Category T1 Lung Adenocarcinoma

Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma

Construction of brain metastasis prediction model in limited stage small cell lung cancer patients without prophylactic cranial irradiation

CT-Based Radiomics Model for Predicting Brain Metastasis in Category T1 Lung Adenocarcinoma

A Novel Mitochondrial-Related Nuclear Gene Signature Predicts Overall Survival of Lung Adenocarcinoma Patients

Risk factors and a new nomogram for predicting brain metastasis from lung cancer: a retrospective study

Radiomics Based on Brain-to-tumor Interface Enables Prediction of Metastatic Tumor Type of Brain Metastasis: a Proof-of-concept Study

Development and Validation of a Nomogram for the Prediction of Brain Metastases in Small Cell Lung Cancer.

Application of Radiomics Signature Captured from Pretreatment CT to Predict Brain Metastases in Stage III/IV Non-small Cell Lung Cancer Patients with ALK Mutation

Integrated proteomic and glycoproteomic analysis reveals heterogeneity and molecular signatures of brain metastases from lung adenocarcinomas